Karyopharm Therapeutics（KPTI）株式概要
商業段階の製薬会社であるカリオファーム・セラピューティクス社は、癌やその他の疾患の治療のために核輸出を阻害する薬剤の発見、開発、商業化を米国で行っている。 詳細
KPTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Karyopharm Therapeutics Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$7.18 |
| 52週高値 | US$10.99 |
| 52週安値 | US$3.65 |
| ベータ | 0.81 |
| 1ヶ月の変化 | -20.22% |
| 3ヶ月変化 | -17.94% |
| 1年変化 | 47.74% |
| 3年間の変化 | -72.33% |
| 5年間の変化 | -94.55% |
| IPOからの変化 | -97.02% |
最新ニュース
Seeking Alpha • Jul 21
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead
Summary Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead. The SENTRY trial in myelofibrosis patients showed mixed results on the co-primary endpoints, but a preliminary survival benefit may strengthen with mature data. Prior SIENDO trial data in endometrial cancer revealed a potential benefit for selinexor in certain subgroups, supporting the upcoming XPORT-EC-042 readout. KPTI faces cash burn and debt concerns, but positive trial results and potential treatment guideline inclusion for selinexor in myelofibrosis could provide it with strategic options. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 08
KPTI: Elevated Expectations For 2026 Revenue Will Likely Constrain Future Upside
Analysts have raised their fair value estimate for Karyopharm Therapeutics from $5.00 to $7.31, citing updated assumptions about discount rates, revenue growth, profit margins, and future P/E, which are reflected in recent price target increases from the Street. Analyst Commentary Recent Street research on Karyopharm Therapeutics highlights a mix of optimism around the company’s potential and caution around how that potential is reflected in the stock price.
ナラティブ更新 • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.ナラティブ更新 • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.Recent updates
Seeking Alpha • Jul 21
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead
Summary Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead. The SENTRY trial in myelofibrosis patients showed mixed results on the co-primary endpoints, but a preliminary survival benefit may strengthen with mature data. Prior SIENDO trial data in endometrial cancer revealed a potential benefit for selinexor in certain subgroups, supporting the upcoming XPORT-EC-042 readout. KPTI faces cash burn and debt concerns, but positive trial results and potential treatment guideline inclusion for selinexor in myelofibrosis could provide it with strategic options. Read the full article on Seeking Alphaナラティブ更新 • Jul 08
KPTI: Elevated Expectations For 2026 Revenue Will Likely Constrain Future Upside
Analysts have raised their fair value estimate for Karyopharm Therapeutics from $5.00 to $7.31, citing updated assumptions about discount rates, revenue growth, profit margins, and future P/E, which are reflected in recent price target increases from the Street. Analyst Commentary Recent Street research on Karyopharm Therapeutics highlights a mix of optimism around the company’s potential and caution around how that potential is reflected in the stock price.ナラティブ更新 • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.ナラティブ更新 • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.ナラティブ更新 • May 03
KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future Upside
Analyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.ナラティブ更新 • Apr 19
KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future Returns
Analysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.ナラティブ更新 • Apr 04
KPTI: Funding Strains And Execution Risks Will Likely Restrain Future Upside
The Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.ナラティブ更新 • Mar 21
KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity
Analysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.
ナラティブ更新 • Mar 07
KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish Repricing
Analysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.ナラティブ更新 • Feb 20
KPTI: Execution And Funding Risks Will Likely Cap Bullish Repricing
Analysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.ナラティブ更新 • Feb 06
KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III Milestone
Analysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.ナラティブ更新 • Jan 23
KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III Milestone
Narrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.分析記事 • Jan 11
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...ナラティブ更新 • Jan 09
KPTI: Financing Overhangs Will Likely Outweigh MF Timeline Support
Analysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.ナラティブ更新 • Dec 25
KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution Risk
Analysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.ナラティブ更新 • Dec 11
KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III Readout
Analysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.ナラティブ更新 • Nov 27
KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III Data
Analysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.ナラティブ更新 • Nov 11
KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future Opportunity
Karyopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.ナラティブ更新 • Oct 28
Extended Cash Runway Will Support Pivotal Phase III Clinical Milestones
Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.ナラティブ更新 • Oct 13
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.分析記事 • Sep 11
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...ナラティブ更新 • Aug 15
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.分析記事 • Aug 14
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results
NasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...分析記事 • May 24
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%
Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...分析記事 • May 22
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet
Key Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
新しいナラティブ • Apr 08
Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.分析記事 • Dec 24
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...分析記事 • Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...分析記事 • Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its second-quarter result this...株主還元
| KPTI | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -24.7% | -1.4% | -1.4% |
| 1Y | 47.7% | 28.1% | 16.4% |
業界別リターン: KPTI過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: KPTI過去 1 年間で16.4 % の収益を上げたUS市場を上回りました。
価格変動
| KPTI volatility | |
|---|---|
| KPTI Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: KPTIの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: KPTIの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2008 | 228 | Richard Paulson | www.karyopharm.com |
Karyopharm Therapeutics Inc.は商業段階の製薬会社で、米国において癌やその他の疾患の治療のために核輸出を阻害する薬剤の発見、開発、商業化を行う。同社は、核輸出タンパク質エクスポートイン1（XPO1）を阻害する新規低分子核輸出選択的阻害剤（SINE）化合物を発見、開発、商業化している。同社のリード化合物には、成人多発性骨髄腫患者を対象としたボルテゾミブおよびデキサメタゾンとの併用療法、成人再発・難治性多発性骨髄腫患者を対象としたデキサメタゾンとの併用療法、成人再発・難治性びまん性大細胞型B細胞リンパ腫（DLBCL）患者を対象としたXPOVIOがある。また、多発性骨髄腫、子宮内膜がん、骨髄線維症、DLBCLを含む血液がんおよび固形がん悪性腫瘍の治療薬としてSelinexorを、その他の骨髄増殖性新生物およびTP53野生型固形がんの治療薬としてELTANEXORを開発している。また、メナリーニ・グループとは、ヒトがんを適応症とするセリンエキソールの開発および商業化に関するライセンス契約を、Antengene Therapeutics Limitedとは、ヒトがんを適応症とするセリンエキソール、エルタネキソール、KPT-9274の開発および商業化、ならびにヒトがん以外の適応症の診断、治療、予防を適応症とするベルジネキソールの開発および商業化に関するライセンス契約を、FORUS Therapeutics Inc.とは、XPOVIOの商業化に関する販売契約を締結している。また、ブリストル・マイヤーズ スクイブ社とは、再発または難治性の多発性骨髄腫患者を対象に、新規のセレブロンE3リガーゼモジュレーターであるメジグドミドとセリンエキソールの併用療法を評価する共同研究を行っている。カリオファーム・セラピューティクス社は2008年に設立され、マサチューセッツ州ニュートンに本社を置いている。
Karyopharm Therapeutics Inc. 基礎のまとめ
| KPTI 基礎統計学 | |
|---|---|
| 時価総額 | US$178.24m |
| 収益（TTM） | -US$194.97m |
| 売上高(TTM) | US$151.12m |
1.1x
P/Sレシオ-0.8x
PER（株価収益率KPTI は割高か？
公正価値と評価分析を参照収益と収入
| KPTI 損益計算書（TTM） | |
|---|---|
| 収益 | US$151.12m |
| 売上原価 | US$130.79m |
| 売上総利益 | US$20.33m |
| その他の費用 | US$215.30m |
| 収益 | -US$194.97m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -8.60 |
| グロス・マージン | 13.45% |
| 純利益率 | -129.02% |
| 有利子負債／自己資本比率 | -111.7% |
KPTI の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/22 07:57 |
| 終値 | 2026/07/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Karyopharm Therapeutics Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20
| アナリスト | 機関 |
|---|---|
| Colleen Kusy | Baird |
| Ying Huang | BofA Global Research |
| Harshita Polishetty | B. Riley Securities, Inc. |